Bone marrow dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTA0,Tyr3octreotate

(1) After PRRT with (177)Lu-DOTA(0),Tyr(3)octreotate, the radioactivity concentration in the bone marrow is identical to that in the blood; (2) There is no significant binding of the radiopharmaceutical to bone marrow precursor stem cells; (3) The contribution of the cross dose from source organs and tumours to the bone marrow dose is significant; and (4) There is considerable variation in bone marrow absorbed dose between patients. These findings imply that for individual dose optimization, individual calculation of the bone marrow absorbed dose is necessary.